miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation.
about
Regulatory Mechanisms of the Molecular Pathways in Fibrosis Induced by MicroRNAsMini-review: emerging roles of microRNAs in the pathophysiology of renal diseasesRole of the microRNA-29 family in fibrotic skin diseases.Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.miR-382 Contributes to Renal Tubulointerstitial Fibrosis by Downregulating HSPD1.Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients.Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in miceDownregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease.microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway.Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosis.MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.MicroRNA-210 Plays a Critical Role in the Angiogenic Effect of Isoprenaline on Human Umbilical Vein Endothelial Cells via Regulation of Noncoding RNAsAlpinia oxyphylla Miq. extract changes miRNA expression profiles in db-/db- mouse kidneyThe signaling pathway of hypoxia inducible factor and its role in renal diseases.MicroRNAs in IgA nephropathy.Role of microRNA machinery in kidney fibrosis.Hypoxia-sensitive pathways in inflammation-driven fibrosis.Biomarkers in IgA nephropathy.Epigenetics in idiopathic pulmonary fibrosis.miRNAs in urine: a mirror image of kidney disease?microRNAs in glomerular diseases from pathophysiology to potential treatment target.Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome.Extracellular microRNA signature in chronic kidney disease.Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis.MicroRNA-29: A Crucial Player in Fibrotic Disease.The Tubulointerstitial Pathophysiology of Progressive Kidney Disease.Hypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function.Novel Anti-fibrotic Therapies.MicroRNA-489 Induction by Hypoxia-Inducible Factor-1 Protects against Ischemic Kidney Injury.Renal Protection Mediated by Hypoxia Inducible Factor-1α Depends on Proangiogenesis Function of miR-21 by Targeting Thrombospondin 1.Hypoxia-inducible factor-1α promotes glomerulosclerosis and regulates COL1A2 expression through interactions with Smad3.MicroRNA and Renal Allograft MonitoringmiR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy.MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis.Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. [corrected].Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling.Differential expression of urinary exosomal microRNAs in IgA nephropathy.MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?A PEG-based method for the isolation of urinary exosomes and its application in renal fibrosis diagnostics using cargo miR-29c and miR-21 analysis.Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.
P2860
Q28072792-1333704F-7987-4EFF-A853-0AAE445818AAQ28354033-5EF57DD9-FE59-44F5-9987-6C80EBD5B108Q33742115-DAC7A002-2471-4C5C-B8F2-A73C5D4217A3Q33754900-C9FBD11C-2018-41D0-A2F3-D5CF8E4B39F3Q33820023-0354FBF9-04F7-46A0-B6A3-73ED3CCBF089Q35070398-29863FF2-3689-4570-A908-A55888B2116FQ35261976-B7619D33-D5DD-467A-B06D-4E818BB7938BQ35405370-50AF4E91-DC03-44A5-B2B4-7801108DA7FAQ35740215-20CE7CC9-5832-4BD4-9A5D-DA76B14F3BD6Q35877447-F3416E78-0E07-49B7-BCCA-952D8C3D9E5DQ37211825-4B09F2DC-E80C-4D1B-9C09-43BC6350E615Q37447462-C1D1C875-2F56-409D-AB39-5EF88B15119EQ37673402-8FC1CE4F-AFF5-487F-9546-3E4A32CED106Q38131006-DF845ED8-AE60-4A87-846B-651E5E4707DFQ38202828-F8ADE43D-443B-4109-AF44-B802EA818EB9Q38209551-750F8843-7CC9-4832-8483-5BA6FA4BA6A6Q38258327-F7E78913-F5F9-4C41-BC44-4C91D3A09810Q38294669-3A44B58B-958E-4543-A6CD-AF4BE6DFC48EQ38346940-4AB43552-9817-4206-BEE5-7FC2235C17B8Q38347455-88756CD0-2DD0-435A-AF09-3B0E58D6393AQ38424330-4F4744C5-594A-44BE-8451-68BF89730A7BQ38646836-358E38B5-C8CB-4CEC-A186-0F7F0FE2A37EQ38721838-690FECF5-3BDE-4A37-B832-C9282B1ABB46Q38754000-465C484F-CA1E-4AA4-8283-C226F8AAE383Q39107249-5708029B-74BA-43B2-8BA8-9932AC8ACD82Q39173994-F2FAD54D-17BD-40D5-9906-57DB077E2CBEQ39277299-EDE35B90-9E28-49E3-8AA8-1494F6B641ADQ39377055-A21CAFBC-8F3D-4FB7-8FFC-D4B59E31ECC3Q40974313-BFB2B86F-C7B9-4E6F-B3FD-9369056A5A04Q41239969-3BD0E72F-7DDD-4FFA-9249-C29190171A51Q41652349-2065CD7D-A9F1-401D-A1EF-079A94127D46Q42017986-41337D54-40FF-49F3-A23E-6D35649AF3E2Q42140252-10E9C1EB-3901-4644-A508-CE6DECAF79CEQ44259722-32229644-4389-4665-8101-B3B7A8B89D9FQ46623958-2A07DD74-0427-449B-BE3F-BDDABC064174Q46632595-0709AD39-9652-4B22-81BD-0376D317D6B0Q48313044-6ED32312-E03E-442D-BBE3-80896D59E9A8Q49626137-6F4F52E5-9ACB-494A-8D53-79F078D8EC6CQ50057516-3BDB093C-6D53-46E3-9327-B1E72496D568Q50063239-97B4B0E5-8EA1-49F7-8297-8B8B446F3410
P2860
miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
miR-29c is downregulated in re ...... restored by HIF-α activation.
@en
type
label
miR-29c is downregulated in re ...... restored by HIF-α activation.
@en
prefLabel
miR-29c is downregulated in re ...... restored by HIF-α activation.
@en
P2093
P2860
P1476
miR-29c is downregulated in re ...... restored by HIF-α activation.
@en
P2093
Alison J Kriegel
Mingyu Liang
Xialian Xu
Xiaofang Yu
Xiaoqiang Ding
Yanyan Heng
P2860
P304
P356
10.1152/AJPRENAL.00287.2012
P577
2013-03-06T00:00:00Z